Stay updated with breaking news from Joel sendek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ Oppenheimer & Co. Inc. (Oppenheimer) a leading investment bank, wealth manager and a subsidiary of Oppenheimer Holdings (NYSE: OPY) today. ....
/PRNewswire/ Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –. ....
/PRNewswire/ Oppenheimer & Co. Inc. ("Oppenheimer") – a leading investment bank, wealth manager, and a subsidiary of Oppenheimer Holdings (NYSE: OPY) –. ....
Editas Medicine James Mullen takes over as CEO from Feb. 15. Editas chairman Mullen will don the CEO mantle Feb. 15, taking over for current Editas chief Cynthia Collins. Before jumping to the Editas team, Mullen was CEO and director of the CDMO Patheon later snapped up by Thermo Fisher and also served as the CEO of Biogen. In a brief release, Editas didn’t say why Collins was leaving. “It has been a privilege to lead Editas Medicine and this extremely talented team,” she said in a statement. “I am particularly proud of the progress to the clinic we have made with both in vivo and ex vivo gene edited medicines.” Collins joined Editas in 2019, picking up the role from ....
Dewpoint Therapeutics Appoints Joel Sendek as Chief Financial Officer - Sendek adds 30 years experience in biotechnology leadership News provided by Share this article Share this article BOSTON, Feb. 11, 2021 /PRNewswire/ Dewpoint Therapeutics, the biomolecular condensates company, today announced it has appointed Joel Sendek as Chief Financial Officer and Treasurer. As we accelerate our growth plans, Joel s financial expertise and leadership in fundraising and corporate finance for both private and public biotech companies will be invaluable, said Ameet Nathwani, M.D., Chief Executive Officer of Dewpoint Therapeutics. I am delighted to welcome him to our rapidly growing team and look forward to the significant contributions he will make as we work to leverage biomolecular condensates to create medicines for some of the world s toughest diseases. ....